ENVB · Enveric Biosciences, Inc. · Executive Compensation
$1.48
+0.06 (+4.23%)
At close · Sep 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.36M
Shares
4.48M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Joseph Tucker | Chief Executive Officer | $879,541 |
| Kevin Coveney | Chief Financial Officer | $678,445 |
| Peter Facchini | Chief Innovation Officer | $253,172 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Joseph Tucker | Chief Executive Officer | $611,533 |
| Kevin Coveney | Chief Financial Officer | $478,002 |
| Peter Facchini | Chief Innovation Officer | $274,580 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Joseph Tucker | Chief Executive Officer | $577,094 |
| Kevin Coveney | Chief Financial Officer | $358,677 |
| Peter Facchini | Chief Innovation Officer | $282,091 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Avani Kanubaddi | Former President and Chief Operating Officer ^^ | $1,300,597 |
| Joseph Tucker | Chief Executive Officer ^^ | $825,937 |
| Peter Facchini | Chief Innovation Officer ^^ | $332,375 |
| Kevin Coveney | Chief Financial Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Avani Kanubaddi | Former President and Chief Operating Officer ^^ | $4,236,593 |
| Peter Facchini | Chief Innovation Officer | $1,704,608 |